(Table 3) Dulaglutide was shown to be dominant versus liraglutide in Colombia, Iran, and Spain by gaining 0.082, 0.157, and 0.022 additional QALYs while saving $2579.94, $1084.37, and $1926.58, respectively [24, 26, 28]
Nothing is one-size-fits-all
A comprehensive look at compounded semaglutide explains the differences, quality considerations, and what to look for
32 Nevertheless, some aspects of the 3142 segment of the GIP remain undiscovered, as GIP (330) is an antagonist while GIP (342) is a partial agonist of GIPR
I propose that targeting a single symptom/component of the disease, i.e., a single building block of the PAIS basin of attraction is unlikely to modify its depth enough to give a chance of escaping this attractor
I love how quickly Dysport softens the wrinkles, without giving you the "frozen look"